Microbot Medical MBOT Proceeds from maturities of marketable securities
Proceeds from maturities of marketable securities at other companies
Other financials
Where this comes from
Reported directly by Microbot Medical in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities.
The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Microbot Medical's proceeds from maturities of marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Microbot Medical's proceeds from maturities of marketable securities?
- Microbot Medical (MBOT) reported proceeds from maturities of marketable securities of $6.5M in Q1 2026.
- How has Microbot Medical's proceeds from maturities of marketable securities changed year-over-year?
- Microbot Medical's proceeds from maturities of marketable securities increased by 96.9% year-over-year, from $3.3M to $6.5M.
- What is the long-term trend for Microbot Medical's proceeds from maturities of marketable securities?
- Over 3 years (2021 to 2025), Microbot Medical's proceeds from maturities of marketable securities has grown at a 52.3% compound annual growth rate (CAGR), from $3M to $10.6M.
- What does proceeds from maturities of marketable securities mean?
- Tracks the cash proceeds received from the sale or maturity of marketable securities held in the company's investment portfolio. This metric demonstrates the company's capacity to convert liquid investments into cash to support ongoing operations or R&D. It is a vital indicator of the company's secondary liquidity sources.